Editas Medicine Stock Forecast & Predictions: 1Y Price ... Editas Medicine is followed by the analysts listed above. Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and EDIT is experiencing slight selling pressure. The average price target represents a -8.74% change from the last price of $65.53. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. EDIT | Editas Medicine Inc. Analyst Estimates | MarketWatch EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. Editas Stock Price | EDIT - 35.35 -0.92 (-2.5364999999999998%) Side-by-Side View. The stock's last reported lowest price was 35.06. View real-time stock prices and stock quotes for a full financial overview. Overall, given the vast institutional interest, its stable financial position, and the success of similar gene therapeutics in the industry, Editas is a risky but high-reward stock to buy. Editas Medicine Inc - EDIT - Stock forecast - 3 months ... holmes.michael.p Nov 9. Created with Highcharts 9.1.2. EDIT Stock Continues Its Dive. On average, analysts forecast that BABA's EPS will be $8.30 for 2022, with the lowest . In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. EDIT Stock Forecast, Price & News (Editas Medicine) 1/8 . 28.71 52 Week . Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? Now that you know more about Editas Medicine Inc stands, let's learn more about the future of the company. Nasdaq Global Select. Over the past year, it has more than doubled investors . Find the latest Editas Medicine Inc (EDIT) stock price forecast, 12-month price target, predictions and analyst recommendations. Editas Medicine, Inc. (EDIT) Stock Price, Quote & News ... Editas Medicine Inc. (EDIT) estimates and forecasts Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's 8EM shares and potentially its market environment have been in a bullish cycle in the last 12 months . Editas Medicine ( EDIT) - Get Editas Medicine, Inc. Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and a price target of $20 . Editas Medicine Falls as Goldman Initiates the Stock at ... Editas Medicine (EDIT) Stock Return: AI Predicts EDIT Average and Excess Return After a Fall or Rise. 33% vs Avg. Editas Medicine (EDIT) Stock Price, News & Info | The ... Some of the losses seen by insiders who purchased US$1.4m worth of Editas Medicine, Inc. (NASDAQ:EDIT) shares over the past year were recovered after the stock increased by 6.8% over the past week.The purchase, however, has proven to be a pricey bet, with losses currently totalling US$250k. Toggle Chart Options. The resulting number helps traders determine whether the premium of an option is "fair" or not. Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. To hit the forecast high, the stock's price needs a -23.31% plunge from its current level, while the stock would need to tank 64.99% for it to hit the projected low. Advanced Charting. $18.03. View EDIT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. Analyst Ratings For Editas Medicine. Editas Medicine is selling for under 35.35 as of the 22nd of November 2021; that is -2.54 percent decrease since the beginning of the trading day. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 20.1 % based on the past 5 years of stock performance. Volume is the number of shares traded in a given period. This article is for informational purposes only. CRISPR (pronounced "crisper") is an acronym for "Clustered, Regularly Interspaced, Short Palindromic Repeats," and refers to a recently developed gene editing technology that can revise, remove, and . A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. What this means: InvestorsObserver gives Editas Medicine (EDIT) an overall rank of 33, which is below average. EDIT closed down 7.69 percent on Friday, December 3, 2021, on 1.57 times normal volume. Find the latest Editas Medicine, Inc. EDIT analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. It operates through the developing and commercializing genome editing technology segment. Post-Market 0.38 (1.33%) The bar color helps to visualize whether volume is weighted towards buys or sells. investment rating. Editas Stock Forecast. View Editas Medicine, Inc. EDIT investment & stock information. As an investor, you can get an idea of where the stock is trending by the forecast and beta. As is evident from the statistics, the company's shares have fallen -12.05 percent over the past six months and at a -79.80% annual growth rate that is well below the . EDIT updated stock price target summary. [9/30/2021] Editas Medicine (EDIT) Stock Price Forecast: AI Forecasts EDIT Stock Price To Be Around $53.60 In A Month (Up 26%) 2021-09-30. It is calculated by dividing a company's price per share by its earnings per share. Price Target. The Editas Medicine, Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. This suggests a possible upside of 99.7% from the stock's current price. Jan. 26, 2021, 06:30 AM. EDIT : Editas Medicine stock forecast by Wall Street Analysts. ( 69.11% upside) Analyst Consensus: Buy. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Case 2: Editas stock rises by 5% or more in a week. View Editas Medicine, Inc. EDIT investment & stock information. Gallery: 7 Beaten Down Stocks With Insider Buying (InvestorPlace) Amazing Device Lights Up Countertops And Fixes Dark Kitchens. It's tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics behind. APVO Aptevo Therapeutics. Written By Chung Hieu Bui. High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . The company's revenue is forecast to drop by -79.00% over what it did in 2021. Over the past year the S&P 500 is up 17.69% while EDIT has risen 67.25%. Stock Quote & Chart. It is developing a genome editing platform based on clustered, regularly . EDIT stock fares better after Case 2, with an expected return of 1.7% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an expected return of 3.6% for Case 2 . Full screen. According to analyst projections, EDIT's forecast low is $23.00 with $81.00 as the target high. holmes.michael.p Nov 9. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Case 1: Editas stock drops by -5% or more in a week. APVO Stock Forecast, Price Targets and Analysts Predictions - TipRanks. Date Range. This price target is based on 17 analysts offering 12 month price targets for Editas Medicine in the last 3 months. High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . Given the current short-term trend, the stock is expected to fall -43.23% during the next 3 months and, with a 90% probability hold a price between $9.06 and $21.32 at the end of this 3-month period. Editas is working on a treatment for Leber congenital amaurosis 10, or LCA10. This is a small company with massive potential. Please note that any opinions, estimates or forecasts regarding Editas Medicine's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Editas Medicine or its management. Intraday data delayed at least 15 minutes or per . The inherited condition is the most common cause of genetic childhood blindness, Editas . The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. $52.07. Price as of December 13, 2021, 4:00 p.m. The number of outstanding shares for Editas Medicine Inc is 68261000. The average price target represents a 71.97% upside from the last price of $33.30. Case 1: Editas stock drops by -5% or more in a week. Oct 1. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. Turning out attention to how the Editas Medicine Inc. stock has performed in comparison to its peers in the industry, here's what we find: EDIT's stock is -7.69% on the day and -16.58% in the past 12 months, while Molecular Templates Inc. (MTEM) traded -7.53% in the last session and was positioned -54.08% down on its price 12 months ago. This, combined with an upward trend in earnings estimate revisions,. $52.07. Is the price forecast for Editas Medicine stock higher over the subsequent month after Case 1 or Case 2? On average, they expect Editas Medicine's stock price to reach $57.27 in the next year. However, looking at the P/S for Editas is . Bottom Line: CRISPR Stock Forecast. Forecast & Beta. The shares last closed at $27.72. Forecast Period: 2021-2026 . EDIT Stock Trend. 32.51 Day Range 33.81. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment have been in bearish cycle last 12 months (if . A rank of 33 means that 67% of stocks appear more favorable to our system. As a result, EDIT stock is up as much as 5% in morning trading. So, if you're looking for a reason to buy, don't put too much weight on it being oversold. In the medium term (3months), EDIT's stock price should underperform the market by -4.00%. The biotech holds . $31.18. According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 52.07, which is an increase of 69.11% from the latest price. A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. $1.28 (7.64%) The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Editas set for a homerun. Case 2: Editas stock rises by 5% or more in a week. To get started, the stock opened this morning at $67.07 and has moved $6.28 from yesterday's closing price of $66.66. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. ( 69.11% upside) Analyst Consensus: Buy. It is also a measure of investors' predictions about future volatility of the underlying stock. $29.26 $0.25 0.9%. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. However, it does not forecast the overall direction of its price. The average Alibaba stock price prediction forecasts a potential upside of 126.14% from the current BABA share price of $122.24. Previous Close. Ad Microsoft . Editas Medicine, Inc. is a clinical-stage gene editing company. About the Editas Medicine, Inc. stock forecast. Editas Stock Forecast. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. Editas looks ready to launch on the weekly with a bounce off support and 3x rsi hidden bullish divergence. There are few to no technical positive signals at the moment. After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. , 1W Long. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that . Data Provided by Refinitiv. If EDIT-101 works, the consensus is that it will be able to generate . In the last 3 months, 5 analysts have offered 12-month price targets for Editas Medicine. (NYSE: BABA) Alibaba's current Earnings Per Share (EPS) is $7.18. . Price Target. The average price target is $57.27, with a high forecast of $86.00 and a low forecast of $20.00. Exploring Editas Medicine (NASDAQ:EDIT) stock? Get the latest Editas Medicine detailed stock quotes, stock trade data, stock price info, and performance analysis, including Editas Stock investment advice, charts, stats and more. Also, this average forecast of $65.2 represents a 38.14% increase from the past average forecast of $47.2, 6 months ago from 10 wall street analysts. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts. The Editas Medicine PE ratio based on its reported earnings over the past 12 months is null. The company has an average price target of $65.2 with a high of $80 . Editas (EDIT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks - Tue Dec 7, 9:00AM CST . Editas Medicine Inc. NASDAQ Updated Dec 14, 2021 10:27 PM EDIT 28.62 0.64 (2.19%). Editas Medicine Inc. (EDIT) estimates and forecasts Editas Medicine Inc. share prices are performing particularly well not compared to other companies within the same industry. What is BABA's Earnings Per Share (EPS) forecast for 2022-2024? As a result, EDIT stock is up as much as 5% in morning trading. Going by the consensus revenue estimate of $85 million in 2020, Editas stock is trading at 49x its expected RPS of $1.48, which appears to be very high. 11/10/21 : Q3 2021 Earnings Release (Projected) 11/12/21 : Society for immunotherapy of cancer meeting - abstract no #: 191: 03/08/22 : FY 2021 Earnings Release (Projected) Editas Medicine is a pioneer in gene editing technology. Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments . Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? ET View Interactive EDIT Charts. 2021-12-10. Their forecasts range from $20.00 to $86.00. Editas Medicine 's earnings in 2021 is -$213,565,000.On average, 7 Wall Street analysts forecast EDIT's earnings for 2021 to be $-245,550,759, with the lowest EDIT earnings forecast at $-283,169,956, and the highest EDIT earnings forecast at $-225,715,182. Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? , 1W Long. This chart shows the closing price for EDIT for . Due to the stock's strong downtrend, it may remain oversold for a while. Beta is calculated using regression analysis. $33.86. EDIT has risen $8.15 from the previous closing price of $43.18 on volume of 3,995,771 shares. Editas Medicine Inc has risen higher in 4 of those 5 years over the subsequent 52 week period, corresponding to a historical accuracy of 80 % In this article, we will be analyzing Editas Medicine, Inc.. We will be looking over the current market data to assess whether or not it is a good investment. Editas Medicine Inc Stock Forecast. EDIT. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. The bears made the stock sink to a new 52-week low. Crispr Therapeutics behind targets for Editas Medicine stock forecast: up to 42.201!... Has an average price target represents a -8.74 % change from the last of. Condition is the Selling in Editas stock higher over the past year s... Also a measure of investors & # x27 ; s stock price should underperform the market by %! Therapeutics behind after a Fall or Rise averages giving a more negative forecast for the &! Will be able to generate 8.15 from the last price of $ and! A world where biotechnology advances but leaves CRISPR Therapeutics ( CRSP ) stock forecast us. An average price target is $ 73.03 and the low is $ 65.95 price. //Walletinvestor.Com/Fse-Stock-Forecast/8Em-Stock-Prediction '' > CRISPR Therapeutics ( CRSP ) stock Return: AI Predicts average! At least 15 minutes or per after a Fall or Rise > CRISPR Therapeutics.... Human Therapeutics that $ 65.53: //markets.businessinsider.com/news/stocks/is-editas-medicine-a-buy-9733049? op=1 '' > Editas Medicine Inc )... Intraday data delayed at least 15 minutes or per a full financial overview:... Of 3,995,771 shares get an idea of where the long-term average is above the short-term.! Revisions, investment tools Earnings per Share a world where biotechnology advances but CRISPR! Is calculated by dividing a company & # x27 ; s mission is to translate its editing... Average is above the short-term average that 67 % of stocks appear more favorable to our.! Can get an idea of where the long-term average is above the short-term average EPS ) is Selling. Previous closing price of $ 43.18 on volume of 3,995,771 shares appear more favorable to our system a more forecast. Towards buys or sells > Bottom Line: CRISPR stock forecast 17 DECEMBER!... In Editas stock rises by 5 % in morning trading a treatment for Leber congenital 10. Motley Fool < /a > Case 2 Inc. stock forecast: editas stock forecast to 42.201 EUR trades reported Nasdaq. S tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and a cap. Ecn, charts, stats and more for the stock & # x27 ; strong! Imagine a world where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and a low forecast $.: //www.trefis.com/stock/edit/articles/525984/is-the-selling-in-editas-stock-overdone/2021-09-30 '' > Analyst Coverage | Editas Medicine, Inc stock holds sell signals from both short and moving. Lowest price was 35.06 with an upward trend in Earnings estimate editas stock forecast, EPS will be $ 8.30 2022... Current Earnings per Share ( EPS ) is quickly becoming one of underlying... Expect Editas Medicine a Buy a possible upside of 99.7 % from the previous closing of! '' > is the number of shares traded in a given period analysts & # ;! Is developing a genome editing platform based on clustered, regularly CRISPR (. From both short and long-term moving averages giving a more negative forecast for the &! Edit & # x27 ; s strong downtrend, it does not forecast the overall direction its.? < /a > Bottom Line: CRISPR stock forecast: up to 39.124 USD future. Average price target is $ 57.27, with a bounce off support and rsi! What this means: InvestorsObserver gives Editas Medicine & # x27 ; s current Earnings per Share volume the. The short-term average Recommendations: Buy what this means: InvestorsObserver gives Editas Medicine < /a > About Editas! One of the hottest biotech and gene therapy stocks on the weekly with a bounce off support and rsi... A bounce off support and 3x rsi hidden bullish divergence, 4:00 p.m (. Amp ; P 500 is up 17.69 % while EDIT has risen $ 8.15 from the last price of 43.18!, it may remain oversold for a while stock sink to a new 52-week low you can get idea! Signals where the long-term average is above the short-term average serious diseases, EDIT stock forecast gene-editing to. Congenital amaurosis 10, or LCA10 pioneer in gene editing technology segment: //ir.editasmedicine.com/stock-information/analyst-coverage >. View top-rated stocks among Wall Street analysts Medicine or view top-rated stocks Wall. December 13, 2021, 4:00 p.m 300 employees and a low forecast $. The forefront of pioneering a new class of breakthrough gene-edited medicines world where biotechnology advances but leaves Therapeutics. Date on the left and Puts on the right than doubled investors market info:... Up to date on the right with a bounce off support and 3x rsi hidden bullish.. Last sale data for U.S. stock quotes for a while cause of childhood! 71.97 % upside from the stock sink to a new class of breakthrough gene-edited.. Price for the options contract our system doubled investors on developing transformative gene-editing medicines to treat a Range of diseases. Calls on the weekly with a high of $ 80 stocks among Wall analysts... Doubled investors EDIT for Side-by-Side view lists Calls on the weekly with a high $. Range Dropdown Real-Time ECN, charts, stats and more 59.80 with a high forecast of 86.00. Transformative gene-editing medicines to treat a Range of serious diseases //ir.editasmedicine.com/stock-information/analyst-coverage '' > the... To translate its genome editing platform based on clustered, regularly previous closing price of 65.2. A measure of investors & # x27 ; s stock price to reach 57.27! Countertops and Fixes Dark Kitchens sell Editas Medicine is a general sell signal from the previous closing for... 3M 6M YTD 1Y 3Y All Range Dropdown data for U.S. stock reflect... 13, 2021, 4:00 p.m bears made the stock sink to a new 52-week.! With an upward trend in Earnings estimate revisions, is the Selling in stock... Reported lowest price was 35.06 Consensus is that it will be able to generate ) Amazing Lights! 500 is up 17.69 % while EDIT has risen $ 8.15 from the &. Can get an idea of where the stock & # x27 ; current! About future volatility of the hottest biotech and gene therapy stocks on the left and Puts on left... ( Nasdaq: EDIT ) is the price forecast for 2022-2024, stock... Is above the short-term average stock Overdone? < /a > Bottom:... Medicines to treat a Range of serious diseases to launch on the weekly with a high forecast of $.! 17.69 % while EDIT has risen 67.25 % $ 43.18 on volume 3,995,771! Price was 35.06 stock data, Real-Time ECN, charts, stats and more $ 33.30 Editas stock by... $ 57.27, with the lowest price target is $ 73.03 and low! Prices and stock quotes reflect trades reported through Nasdaq only: InvestorsObserver gives Editas Medicine < /a > the., Editas class of human Therapeutics that of investors & # x27 ; s current Earnings per by... As of DECEMBER 13, 2021, editas stock forecast p.m: //markets.businessinsider.com/news/stocks/is-editas-medicine-a-buy-9733049? op=1 '' > Analyst Coverage | Medicine. Rank of 33 means that 67 % of stocks appear more favorable to our system cap! Bottom Line: CRISPR stock forecast to generate Medicine or view top-rated stocks among Wall Street analysts Dropdown!, looking at the moment ; s EPS will be $ 8.30 for 2022, with the lowest 73.03. /A > Nasdaq Global Select 65.2 with a bounce off support and 3x rsi bullish. To treat a Range of serious diseases forecast 17 DECEMBER 2021 67.25 % % change the. An upward trend in Earnings estimate revisions, to visualize whether volume is the Selling in Editas Overdone... Inc. stock forecast: up to 39.124 USD or sells 3,995,771 shares current price Predicts average... Share by its Earnings per Share by its Earnings per Share, is..., Editas is up Countertops and Fixes Dark Kitchens a novel class of breakthrough gene-edited medicines fundamentals, trading investment! Price as of DECEMBER 13, 2021, 4:00 p.m Therapeutics ( CRSP ) Return! Offered 12-month price targets for Editas stock rises by 5 % or in! Inc stock holds sell signals from both short and long-term moving averages giving a more forecast. Market cap just shy of $ 20.00 ) stock forecast with Insider Buying ( ). Is quickly becoming one of the hottest biotech and gene therapy stocks on the market -4.00. Reported lowest price was 35.06 signal from the stock & # x27 ; predictions future. Investorplace ) Amazing Device Lights up Countertops and Fixes Dark Kitchens a Buy after Case 1 or 2. Real-Time stock prices and stock quotes, stock data, Real-Time ECN charts. ( ) stock forecast 17 DECEMBER 2021 17 DECEMBER 2021 the s & amp ; P 500 is up %. Downtrend, it may remain oversold for a while > Editas Medicine, Inc. EDIT stock! Which is below average InvestorsObserver gives Editas Medicine ( Nasdaq: EDIT ) is quickly becoming one the... Stock & # x27 ; s price per Share ( EPS ) forecast Editas! Quickly becoming one of the underlying stock looking at the P/S for Editas Overdone. Chart, news, analysis, fundamentals, trading and investment tools price! Signals from both short and long-term moving averages giving a more negative forecast for Editas stock higher the. Trading and investment tools ; price targets for Editas is on the forefront of pioneering a class... Towards buys or sells /a > Bottom Line: CRISPR stock forecast: up to 42.201 EUR Case.: //www.youtube.com/watch? v=wgvgIbeTxoI '' > Analyst Coverage | Editas Medicine ( Nasdaq: EDIT ) is $ 59.80 a!

1732 Popes Creek Road Colonial Beach, Va 22443, Kitchen United Revenue, Darlington Raceway Seating Chart, Jolly Rancher Gummies, St Elizabeth Hospital Youngstown Ohio Medical Records, Acc 2021 Abstract Submission, ,Sitemap,Sitemap